Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence

Diabetes Care

Volumn 28, Issue 7, 2005, Pages 1769-1778

  Ford, Earl S ^a,b  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PREDICTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SAMPLING;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS; HUMANS; METABOLIC SYNDROME X; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 21544462572     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.7.1769     Document Type: Review

References (42)

1. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
2. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Washington, DC, U.S. Govt. Printing Office, 2001 (NIH Publication no. 01-3670)
3. Vinicor F, Bowman B: The metabolic syndrome: the emperor needs some consistent clothes (Letter). Diabetes Care 27:1243, 2004
4. Ford ES: Insulin resistance syndrome: the public health challenge. Endocr Pract 2 (Suppl. 9):23-25, 2003
5. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156:1070-1077, 2002
6. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959
7. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
8. Tobias A: sbe26: assessing the influence of a single study in meta-analysis. Stata Tech Bull 47:15-17, 1999
9. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
10. Egger M, Davey Smith G, Schneider M, Minder CE: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997
11. Sterne JAC, Bradburn MJ, Egger M: Meta-analysis in stata. In Systematic Reviews in Health Care. Egger M, Smith GD, Altman DG, Eds. London, BMJ Books, 1995. Update is available from http://www.bmjpg. com/books/sysrev/chapter18.pdf. Accessed 26 August 2004
12. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
13. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
14. Katzmarzyk PT, Church TS, Blair SN: Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164:1092-1097, 2004
15. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251-1257, 2004
16. Ford ES: The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173: 309-314, 2004
17. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V: Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels: a prospective and cross-sectional evaluation. Atherosclerosis 165:285-292, 2002
18. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV: Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 26:861-867, 2003
19. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380-385, 2004
20. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M: Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck Study. Diabetes Care 26:1251-1257, 2003
21. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385-390, 2005
22. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391-397, 2003
23. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419, 2003
24. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M, the 4S Group, the AFCAPS/TexCAPS Research Group: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93:136-141, 2004
25. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
26. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM, the San Antonio Heart Study: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 26:3153-3159, 2003
27. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27:2676-2681, 2004
28. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, the DECODE Study Group: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066-1076, 2004
29. Sowers JR, Frohlich ED: Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 88:63-82, 2004
30. Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, Zinman B, Haffner SM: Identification of subjects with insulin resistance and β-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 52:2740-2747, 2003
31. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R: Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabefes Care 26:3320-3325, 2003
32. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT: Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978-983, 2004
33. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES: Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53:1195-1200, 2004
34. Duncan BB, Schmidt MI: Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 119:122-127, 2001
35. Bjorntorp P, Rosmond R: The metabolic syndrome: a neuroendocrine disorder? Br J Nutr 83 (Suppl. 1):S49-S57, 2000
36. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD: Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51:1066-1075, 2002
37. Vitaliano PP, Scanlan JM, Zhang J, Savage MV, Hirsch IB, Siegler IC: A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med 64:418-435, 2002
38. Groop L: Genetics of the metabolic syndrome. Br J Nutr 83 (Suppl. 1):S39-S48, 2000
39. Arya R, Blangero J, Williams K, Almasy L, Dyer TD, Leach RJ, O'Connell P, Stern MP, Duggirala R: Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican Americans. Diabetes 51:841-847, 2002
40. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, the American Heart Association, the National Heart, Lung, and Blood Institute: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438, 2004
41. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lemmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stem M, Tuomilehto J, Zimmet P, the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003
42. Ford ES, Williamson DF, Liu S: Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 146:214-222, 1997